Influenza C virus susceptibility to antivirals with different mechanisms of action-Reference-Cited by-同舟云学术

Influenza C virus susceptibility to antivirals with different mechanisms of action

Published:2024-05-02 Issue:5 Volume:68 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Chesnokov Anton¹^ORCID,Ivashchenko Andrei A.²,Matsuzaki Yoko³,Takashita Emi⁴,Mishin Vasiliy P.¹,Ivachtchenko Alexandre V.²⁵,Gubareva Larisa V.¹

Affiliation:

1. Influenza Division, NCIRD, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA

2. ChemDiv, San Diego, California, USA

3. Department of Infectious Diseases, Yamagata University Faculty of Medicine, Yamagata, Japan

4. Research Center for Influenza and Respiratory Viruses, National Institute of Infectious Diseases, Tokyo, Japan

5. AVISA LLC, Hallandale Beach, Florida, USA

Abstract

ABSTRACT Antiviral susceptibility of influenza viruses was assessed using a high-content imaging-based neutralization test. Cap-dependent endonuclease inhibitors, baloxavir and AV5116, were superior to AV5115 against type A viruses, and AV5116 was most effective against PA mutants tested. However, these three inhibitors displayed comparable activity (EC 50 8–22 nM) against type C viruses from six lineages. Banana lectin and a monoclonal antibody, YA3, targeting the hemagglutinin-esterase protein effectively neutralized some, but not all, type C viruses.

Publisher

American Society for Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01727-23

Reference19 articles.

1. Molecular Characterization of Influenza C Viruses from Outbreaks in Hong Kong SAR, China

2. Host Range, Biology, and Species Specificity of Seven-Segmented Influenza Viruses—A Comparative Review on Influenza C and D

3. Influenza antivirals and their role in pandemic preparedness

4. Properties of influenza C virus grown in cell culture

5. Structural and Biochemical Basis for Development of Influenza Virus Inhibitors Targeting the PA Endonuclease